Helen Higgins

854 total citations
19 papers, 112 citations indexed

About

Helen Higgins is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Helen Higgins has authored 19 papers receiving a total of 112 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 9 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Helen Higgins's work include Breast Cancer Treatment Studies (9 papers), Advanced Breast Cancer Therapies (5 papers) and Multiple Myeloma Research and Treatments (4 papers). Helen Higgins is often cited by papers focused on Breast Cancer Treatment Studies (9 papers), Advanced Breast Cancer Therapies (5 papers) and Multiple Myeloma Research and Treatments (4 papers). Helen Higgins collaborates with scholars based in United Kingdom, Australia and Sweden. Helen Higgins's co-authors include Kryss McKenna, Janet Dunn, David Cameron, Louise Hiller, Helena Earl, Adrian Harnett, Claire Hulme, Carlos Caldas, Shrushma Loi and Richard Simcock and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Helen Higgins

18 papers receiving 109 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Helen Higgins United Kingdom	6	64	37	24	20	17	19	112
Donatella Grasso Italy	9	107 1.7×	25 0.7×	20 0.8×	20 1.0×	26 1.5×	22	159
Ramya Varadarajan United States	5	57 0.9×	21 0.6×	16 0.7×	54 2.7×	9 0.5×	12	148
Luca Campedel France	6	32 0.5×	17 0.5×	17 0.7×	10 0.5×	20 1.2×	26	93
Élise Dumas France	7	124 1.9×	19 0.5×	11 0.5×	4 0.2×	24 1.4×	25	195
B.E. van den Borne Netherlands	6	103 1.6×	25 0.7×	8 0.3×	11 0.6×	32 1.9×	10	210
Roel van Kampen Netherlands	5	75 1.2×	25 0.7×	4 0.2×	10 0.5×	34 2.0×	8	167
Yuriko N. Koyanagi Japan	9	88 1.4×	22 0.6×	10 0.4×	11 0.6×	42 2.5×	18	178
Sucheta More India	6	69 1.1×	34 0.9×	8 0.3×	7 0.3×	17 1.0×	24	141
Pippa Riddle United Kingdom	6	79 1.2×	23 0.6×	42 1.8×	6 0.3×	21 1.2×	15	136
Gianpiero Rizzo Italy	6	35 0.5×	44 1.2×	7 0.3×	6 0.3×	32 1.9×	19	113

Countries citing papers authored by Helen Higgins

Since Specialization

Citations

This map shows the geographic impact of Helen Higgins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Higgins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Higgins more than expected).

Fields of papers citing papers by Helen Higgins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Higgins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Higgins. The network helps show where Helen Higgins may publish in the future.

Co-authorship network of co-authors of Helen Higgins

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Higgins. A scholar is included among the top collaborators of Helen Higgins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Higgins. Helen Higgins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Stein, Robert C., Andrea Marshall, Jane Bayani, et al.. (2024). Abstract PO4-16-02: Can high progesterone receptor (PgR) expression identify tumours with low-risk tumour gene expression scores?. Cancer Research. 84(9_Supplement). PO4–16. 1 indexed citations

Dunn, Janet, Andrea Marshall, Alastair M. Thompson, et al.. (2024). Abstract GS03-02: Mammographic surveillance in early breast cancer patients aged 50 years or over: results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography. Cancer Research. 84(9_Supplement). GS03–2. 2 indexed citations

Goyal, Amit, Andrea Marshall, Duncan Wheatley, et al.. (2023). Abstract OT1-09-02: ATNEC: A multicentre, randomized trial investigating whether axillary treatment can be avoided in T1-3N1M0 breast cancer patients with no residual cancer in the axillary lymph nodes after neoadjuvant chemotherapy. Cancer Research. 83(5_Supplement). OT1–9. 1 indexed citations

Stein, Robert C., Andrea Marshall, Jane Bayani, et al.. (2022). Disparity between Ki67 measurements and tumor gene expression tests in patients with hormone-sensitive early breast cancer from the OPTIMA preliminary trial.. Journal of Clinical Oncology. 40(16_suppl). 567–567. 3 indexed citations

Goyal, Amit, Andrea Marshall, Duncan Wheatley, et al.. (2022). ATNEC: A multicenter, randomized trial investigating whether axillary treatment can be avoided in patients with T1-3N1M0 breast cancer with no residual cancer in the lymph glands after neoadjuvant chemotherapy.. Journal of Clinical Oncology. 40(16_suppl). TPS615–TPS615. 6 indexed citations

Goyal, Amit, Duncan Wheatley, Andrea Marshall, et al.. (2021). Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy (ATNEC).. Journal of Clinical Oncology. 39(15_suppl). TPS600–TPS600. 2 indexed citations

Goyal, Amit, Duncan Wheatley, Andrea Marshall, et al.. (2021). Abstract OT-04-01: Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy - ATNEC (ClinicalTrials.gov NCT04109079). Cancer Research. 81(4_Supplement). OT–4.

Heaney, Jennifer, Gulnaz Iqbal, Janet Dunn, et al.. (2020). Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study. SHILAP Revista de lepidopterología. 7(10). 1–70. 2 indexed citations

Atkin, Catherine, Gulnaz Iqbal, Tim Planche, et al.. (2020). Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial. British Journal of Haematology. 192(6). 997–1005. 5 indexed citations

10.

Audisio, Riccardo A., Andy Evans, Andrea Marshall, et al.. (2020). MAMMO-50: Mammographic surveillance in breast cancer patients over 50 years of age. European Journal of Surgical Oncology. 46(2). e18–e19. 1 indexed citations

11.

Drayson, Mark T., Stella Bowcock, Tim Planche, et al.. (2019). Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT. Health Technology Assessment. 23(62). 1–94. 4 indexed citations

12.

Earl, Helena, Louise Hiller, Anne-Laure Vallier, et al.. (2018). PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.. Journal of Clinical Oncology. 36(15_suppl). 506–506. 40 indexed citations

13.

Drayson, Mark T., Stella Bowcock, Tim Planche, et al.. (2017). Tackling Early Morbidity and Mortality in Myeloma (TEAMM): Assessing the Benefit of Antibiotic Prophylaxis and Its Effect on Healthcare Associated Infections in 977 Patients. Blood. 130(Suppl_1). 903–903. 11 indexed citations

14.

Earl, Helena, David Cameron, David Miles, et al.. (2013). PERSEPHONE: Duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer—Six versus twelve months.. Journal of Clinical Oncology. 31(15_suppl). TPS667–TPS667. 1 indexed citations

15.

Earl, Helena, David Cameron, David Miles, et al.. (2012). The PERSEPHONE trial: Duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer.. Journal of Clinical Oncology. 30(15_suppl). TPS660–TPS660. 5 indexed citations

16.

Earl, Helena, David Cameron, John M.S. Bartlett, et al.. (2012). ARTemis: Randomized trial with neoadjuvant chemotherapy for patients with early breast cancer.. Journal of Clinical Oncology. 30(15_suppl). TPS1144–TPS1144. 2 indexed citations

17.

Poole, Christopher, Andrea Marshall, Helen Higgins, et al.. (2012). Neo-escape: Neoadjuvant extended sequential chemotherapy with adjuvant postoperative treatment for epithelial nonmucinous advanced inoperable peritoneal malignancy.. Journal of Clinical Oncology. 30(15_suppl). 5046–5046. 1 indexed citations

18.

Hiller, Louise, Janet Dunn, Helen Higgins, et al.. (2011). Optimising patient recall of adverse events over prolonged time periods. Trials. 12(S1). 1 indexed citations

19.

McKenna, Kryss & Helen Higgins. (1997). Factors influencing smoking cessation in patients with coronary artery disease. Patient Education and Counseling. 32(3). 197–205. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact